Loading…

Expression of Fas Ligand and Its Receptor in Cutaneous Lupus: Implication in Tissue Injury

Fas ligand (FasL) is a type II membrane protein which belongs to the tumor necrosis factor family. Ligation of its receptor (Fas/APO-1/CD95) by FasL induces apoptosis of Fas-expressing cells. However, thein vivofunction of these molecules in cutaneous immunity is presently unknown. In the present st...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology and immunopathology 1997-06, Vol.83 (3), p.223-229
Main Authors: Nakajima, Michiko, Nakajima, Atsuo, Kayagaki, Nobuhiko, Honda, Mitsuyoshi, Yagita, Hideo, Okumura, Ko
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fas ligand (FasL) is a type II membrane protein which belongs to the tumor necrosis factor family. Ligation of its receptor (Fas/APO-1/CD95) by FasL induces apoptosis of Fas-expressing cells. However, thein vivofunction of these molecules in cutaneous immunity is presently unknown. In the present study, we investigated the involvement of Fas and FasL in the pathogenesis of cutaneous lupus by immunohistochemical methods. In normal skin, expression of Fas was observed on keratinocytes in the basal to granular layers. Unexpectedly, FasL was constitutively expressed on histiocytes in the dermis. In specimens of cutaneous lupus, Fas was expressed on infiltrating lymphocytes, as well as on keratinocytes as observed in normal skin. FasL was expressed on a portion of infiltrating CD4+T cells and on histiocytes more frequently than those in normal skin. Double staining indicated that these FasL-expressing histiocytes were CD68 positive macrophages. Especially, FasL-expressing macrophages were distributed around appendages such as hair follicles. These results suggest the Fas/FasL interaction may be involved in the destruction of hair follicles which is a characteristic feature of cutaneous lupus.
ISSN:0090-1229
1090-2341
DOI:10.1006/clin.1997.4352